Quantcast

Latest RNA interference Stories

2014-10-29 08:33:08

Data Supportive of GEN-2, an RNAi Carrier for Therapeutic Treatment of Lung Cancer LAWRENCEVILLE, N.J., Oct. 29, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today announced the presentation of data related to TheraSilence(TM), the Company's lung-specific RNA delivery technology, at the miRNA World Conference Workshop on miRNA Delivery in Boston, MA. The data was presented by Dr. Khursheed Anwer, Celsion's Executive Vice President and Chief Scientific Officer, during a panel...

2014-10-28 04:22:38

DALLAS, October 28, 2014 /PRNewswire/ -- RnRMarketResearch.com adds RNA Interference Screening Trends 2014 market research and industry survey report to the Biotechnology section of its life sciences intelligence library. This market report summarizes the results of an industry-wide global web-based benchmarking survey on RNA interference (RNAi) screening and gene silencing carried out in October 2014. The questionnaire was compiled to meet the needs, requirements and...

2014-10-27 12:29:40

MOUNTAIN VIEW, Calif., Oct. 27, 2014 /PRNewswire/ -- Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced that they have entered into a non-exclusive license agreement with the Broad Institute to access intellectual property related to the CRISPR/Cas9 gene editing system. http://photos.prnewswire.com/prnvar/20131021/SF99259LOGO "Clontech is pleased to be able to provide innovative tools for CRISPR/Cas9 gene editing under our Guide-it(TM)...

2014-10-21 12:32:38

DUBLIN, Oct. 21, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global RNA Based Therapeutics Market (Technology, Application, End Users and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 A new report titled "RNA Therapeutics Market (technology, applications, end user and...

2014-10-14 16:27:09

LONDON, Oct. 14, 2014 /PRNewswire/ -- This BCC Research report provides an in-depth assessment of recent progress and future opportunities for RNA interference (RNAi) players in major therapeutic and drug delivery areas, including infectious diseases, cancer, inflammation/immune dysfunction, central nervous system (CNS) disorders, and cardiology/metabolism. Known simply as RNAi, this field has rapidly emerged as a fast-growing new market. This report also provides forecasts for market...

2014-10-07 08:28:56

MARLBOROUGH, Mass., Oct. 7, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that a review of the first two enrolled patients' clinical photographs in the first Phase 2a clinical trial (RXI-109-1301), indicate that treatment with the Company's lead clinical candidate, RXI-109, may...

2014-09-29 08:29:58

MARLBOROUGH, Mass., Sept. 29, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company's President and Chief Executive Officer, Dr. Geert Cauwenbergh, will present at the 13(th) Annual BIO Investor Forum on Tuesday, October 7, 2014 at 10:00 a.m. PST. Dr. Cauwenbergh will...

2014-09-18 08:29:06

MARLBOROUGH, Mass., Sept. 18, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company's President and Chief Executive Officer, Dr. Geert Cauwenbergh, will present at the 7(th) Annual BioPharm America(TM) Conference on Wednesday, September 24, 2014 at 11:20 a.m. EDT. Dr....

2014-09-17 08:29:00

Patents granted by the United States Patent and Trademark Office and European Patent Office and a notice of allowance from the Japanese Patent Office broaden the breadth of the Company's delivery technology platform MARLBOROUGH, Mass., Sept. 17, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

2014-09-11 12:27:04

SARASOTA, Fla., Sept. 11, 2014 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that the United States Patent and Trademark Office has issued a 'Notice of Allowance' for patent application 11/673,486 entitled 'Oligonucleotide-Containing Pharmacological Compositions And Their Uses'. The '486 patent application relates to the Company's orally-deliverable nanoRNA therapeutics that act through gene-silencing and can be...


Latest RNA interference Reference Libraries

Blue Rose
2013-10-02 08:33:40

A Blue Rose is a flower of the genus Rosa belonging to the family Rosaceae that presents blue to violet pigmentation instead of the more common white, red, or yellow coloration. Blue roses are frequently portrayed in literature and art as a symbol of love and prosperity to those who seek it, but don’t exist in nature as a result of genetic limitations. In 2004, researchers utilized genetic modification to produce roses that contain the blue pigment delphinidin. After 13 years of...

Caenorhabditis elegans
2014-01-12 00:00:00

Caenorhabditis elegans is a species of parasitic roundworm in the Nematoda phylum. It can be found in temperate regions, in many different areas of the world. It prefers to reside in nutrient rich soils. Its scientific name is derived from the Greek terms Caeno, meaning recent, rhabditis, meaning rod-like, and the Latin term elegans, which means elegant. It was first named by Maupas in 1900, but was not classified in the Caenorhabditis subgenus until 1952 by Osche. Caenorhabditis elegans...

More Articles (2 articles) »
Word of the Day
ambsace
  • Bad luck; misfortune.
  • The smallest amount possible or the most worthless thing.
The word 'ambsace' comes from a Latin word meaning 'both'.